MinorGabapentinoids (antiepileptics)×Biguanides. Oral antihyperglycemic agents
Updated · Methodology
Mechanism
Metformin is not metabolised in the body and is excreted unchanged by the kidneys through glomerular filtration and tubular secretion. It is a substrate of the organic cation transporters OCT1 and OCT2, and OCT2 inhibitors can slow its elimination (metformin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Gabapentin is not metabolised either and is excreted unchanged by the kidneys. Its clearance is directly proportional to creatinine clearance (gabapentin SmPC, AEMPS). The gabapentin documents do not describe it as an inhibitor of OCT2 or of MATE transporters, and probenecid, a blocker of renal tubular secretion, did not change gabapentin elimination (Neurontin label, US Food and Drug Administration, FDA). Gabapentin is not on the lists of drugs that change the elimination or effect of metformin, and metformin is not among the gabapentin interactions (metformin and gabapentin SmPCs, AEMPS; metformin and Neurontin labels, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Gabapentin very commonly causes somnolence, dizziness and ataxia. Raised blood glucose was reported uncommonly and low blood glucose rarely, more often in people with diabetes (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At the start of treatment metformin very commonly causes nausea, vomiting, diarrhoea and abdominal pain. Its very rare but serious complication is lactic acidosis, with acidotic breathlessness, abdominal pain, muscle cramps, weakness and hypothermia, followed by coma (metformin SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of metformin and gabapentin need no change. No document names the pair, and gabapentin is not among the drugs that slow metformin elimination (metformin and gabapentin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; metformin label, US Food and Drug Administration, FDA). During metformin treatment, the usual laboratory tests for diabetes control are done regularly (metformin SmPC, AEMPS). In people with diabetes taking gabapentin, raised blood glucose was reported uncommonly and low blood glucose rarely (gabapentin SmPC, AEMPS). Glomerular filtration rate (GFR) is assessed before metformin starts and at least once a year after that. In older people and in those at risk of worsening renal function, it is assessed every 3–6 months. Metformin is contraindicated when GFR is below 30 mL/min (metformin SmPC, AEMPS). The gabapentin dose is based on creatinine clearance and is reduced according to the SmPC table when creatinine clearance is below 79 mL/min (gabapentin SmPC, AEMPS). In dehydration from severe vomiting, diarrhoea, fever or low fluid intake, metformin is stopped temporarily (metformin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Neurontin 300 mg cápsulas duras (gabapentina) (2026)– AEMPS, CIMA, nº registro 60621, revisión 01/2026, secciones 4.4 y 4.5
- FDA: Neurontin (gabapentin) – Prescribing Information (2026)– FDA, DailyMed SPL, Viatris Specialty, sections 5.8, 7.1 and 12.3
- AEMPS: Ficha técnica Dianben 850 mg comprimidos recubiertos con película (metformina) (2025)– AEMPS, CIMA, nº registro 55211, revisión 03/2025, secciones 4.4 y 4.5
- FDA: Metformin hydrochloride tablets (metformin) prescribing information (2026)– FDA, DailyMed, setid c82a10fa-1e8e-46b6-890a-737de3f34ee1 (Zydus), SPL 07/2026, sections 5.1, 7 and 12.3